Search
2023 Moving towards a rabies-free Southeast Asia_Whitepaper.pdf
pipeline-october-2023
Dynagito
DYNAGITO Infographic
Payments_to_patienten_organisations_2022
Partnering in Parasitology MAY 2024 CORP_0.pdf
BI-access-to-healthcare-strategy
enabling_todays-science_infographic
Manifesto-Infographics
Risk Factors of Venous Thromboembolism (VTE)_0.pdf
Respiratory Research and Development Timeline.pdf
vesuto_ers2018.pdf
Respiratory_Partnering_Interests_2018-12.pdf
Symptoms of VTE.pdf
Most common risk factors for VTE.pdf
Most common risk factors for VTE.pdf
Most common risk factors for VTE.pdf
Praxbind® – the specific reversal agent to dabigatran.pdf
Diabetes dog symptoms chronic disease management
Learn about the symptoms of canine diabetes and how to manage the disease.
Vikas joined from hospital sector
Are you considering moving into pharmaceuticals for the first time? Vikas made the leap and has never looked back.
Access to Healthcare: How we help underserved communities
Access to healthcare is not a given for everyone. We are partnering with an organization in Rome to help underserved communities.
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
A guide to hidradenitis suppurativa (HS)
Hidradenitis suppurativa (HS) is a long-term, inflammatory, recurrent, skin condition that causes painful inflamed nodules, or abscesses on the skin
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic